---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039517"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:30:00.328876+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Indaptus Q3 2023 net loss $0.47/share; cash $16M into Q2 2024; Decoy20 all 4 patients stable disease

## Summary
- Cash and equivalents $16.0M as of Sep 30, 2023, down from $26.4M at Dec 31, 2022; runway into Q2 2024.
- Net loss per share $0.47 for Q3 2023 versus $0.42 year ago; R&D expense $2.2M (up $0.6M YoY).
- Decoy20 Phase 1 first cohort: all four patients maintain stable disease; first patient dosed in second cohort.
- Roger Waltzman, M.D. appointed Chief Medical Officer effective August 7, 2023.

## SEC filing metadata
- accession: 0001493152-23-039517
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315223039517/0001493152-23-039517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315223039517/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039517
- JSON: https://secwatch.observer/filing/0001493152-23-039517.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039517.txt

## Key facts
- Earnings Releases
  Indaptus Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: EPS approximately $0.47.
  - Period: the third quarter ended September 30, 2023
  - EPS: approximately $0.47
  - Result: reported results
  source text: On November 6, 2023, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315223039517/0001493152-23-039517-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.